Abstract
Gene therapy represents a new therapeutic modality for the treatment of acute and chronic inflammatory diseases. Clinical trials are currently underway in patients with hereditary diseases, such as cystic fibrosis and ar antitrypsin deficiency (1) as well as in chronic infectious diseases, like hepatitis C and HIV infections, or in cancer (2,3). Although there has been a great deal of enthusiasm for gene therapy, it still remains unclear and too early to determine whether this new approach will be safe and effective.
Chapter PDF
Similar content being viewed by others
Keywords
- Cystic Fibrosis
- Gene Therapy
- Cystic Fibrosis Transmembrane Conductance Regulator
- Adenoviral Vector
- Feline Immunodeficiency Virus
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Literature Cited
Crystal RG, Jaffe A, Brody S, Mastrangeli A, McElvaney NG, Rosenfeld M, Chu CS, Danel C, Hay J, Eissa T. A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung.Hum Gene Ther.1995;6:643–66.
Crystal RG. Transfer of genes to humans: early lessons and obstacles to success.Science.1995;270:404–10.
Anderson WF. Human gene therapy.Nature.1998;392:25–30.
Gene Therapy Advisory Committee. Report on the potential use of gene therapy in utero. Health Departments of the United Kingdom, November 1998.Hum Gene Ther.1999;10:689–92.
Pilaro AM, Serabian MA. Preclinical development strategies for novel gene therapeutic products.Toxicol Pathol.1999;27:4–7.
Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going?J Natl Cancer Inst.1997;89:21–39.
Marshall E. Gene therapy death prompts review of adenovirus vector.Science.1999;286:2244–5.
Blaese RM. Gene therapy for cancer.Sci Am.1997;276:111–5.
Brigham KL, Canonico AE, Meyrick BO, Schreier H, Stecenko AA, Conary JT. Gene therapy for inflammatory diseases.Prog Clin Biol Res.1994;388:361–5.
Favrot MC. [Gene therapy: a review 6 years after the first trials in man. Round Table No 6 at Giens XIII].Therapie.1998;53:381–4.
Moldawer LL, Edwards PD, Josephs M, Minter RM, Copeland EM, 3rd, MacKay SL. Application of gene therapy to acute inflammatory diseases.Shock.1999;12:83–101.
Crystal RG. The gene as the drug.Nat Med.1995;1:15–7.
Canonico AE, Plitman JD, Conary JT, Meyrick BO, Brigham KL. No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes.J Appl Physiol.1994;77:415–9.
Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT, Danel C. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis.Nat Genet.1994;8:42–51.
Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants.Gene Ther.1995;2:107–15.
Nielsen LL, Gurnani M, Syed J, Dell J, Hartman B, Cartwright M, Johnson RC. Recombinant El-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.Hum Gene Ther.1998;9:681–94.
Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats.Proc Natl Acad Sci USA.1997;94:14083–8.
Varley AW, Geiszler SM, Gaynor RB, Munford RS. A two-component expression system that responds to inflammatory stimuli in vivo.Nat Biotechnol.1997;15:1002–6.
Dusetti NJ, Vasseur S, Ortiz EM, Romeo H, Dagorn JC, Burrone O, Iovanna JL. The pancreatitis-associated protein I promoter allows targeting to the pancreas of a foreign gene, whose expression is up-regulated during pancreatic inflammation.J Biol Chem.1997;272:5800–4.
Massie B, Couture F, Lamoureux L, Mosser DD, Guilbault C, Jolicoeur P, Belanger F, Langelier Y. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette.J Virol.1998;72:2289–96.
No D, Yao TP, Evans RM. Ecdysone-inducible gene expression in mammalian cells and transgenic mice.Proc Natl Acad Sci USA.1996;93:3346–51.
Knowles MR, Noone PG, Hohneker K, Johnson LG, Boucher RC, Efthimiou J, Crawford C, Brown R, Schwartzbach C, Pearlman R. A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis.Hum Gene Ther.1998;9:249–69.
Zhang HG, Zhou T, Yang P, Edwards CK, 3rd, Curiel DT, Mountz JD. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver.Hum Gene Ther.1998;9:1875–84.
Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines.J Immunol.1997;158:3635–9.
Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria.J Immunol.1999;162:2291–8.
Rogy MA, Auffenberg T, Espat NJ, Philip R, Remick D, Wollenberg GK, Copeland EM, 3rd, Moldawer LL. Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses.J Exp Med.1995;181:2289–93.
Denham W, Denham D, Yang J, Carter G, MacKay S, Moldawer LL, Carey LC, Norman J. Transient human gene therapy: a novel cytokine regulatory strategy for experimental pancreatitis.Ann Surg.1998;227:812–20.
Norman J, Denham W, Denham D, Yang J, Carter G, Abouhamze A, Tannahill CL, Mackay S, Moldawer LL. Liposome-mediated, non-viral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation.Gene Therapy. 2000. In press.
Brigham KL, Meyrick B, Christman B, Magnuson M, King G, Berry LC, Jr. In vivo transfection of murine lungs with a functioning prokaryotic gene using a liposome vehicle.Am J Med Sci.1989;298:278–81.
Brigham KL, Meyrick B, Christman B, Berry LC, Jr., King G. Expression of a prokaryotic gene in cultured lung endothelial cells after lipofection with a plasmid vector.Am J Respir Cell Mol Biol.1989; 1:95–100.
Jenkins RG, Herrick SE, Meng QH, Kinnon C, Laurent GJ, McAnulty RJ, Hart SL. An integrin-targeted non-viral vector for pulmonary gene therapy.Gene Ther.2000;7:393–400.
Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, Durham SR, Jeffery PK, Hodson ME, Coutelle C, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis.Nat Med.1995;1:39–46.
Romano G, Pacilio C, Giordano A. Gene transfer technology in therapy: current applications and future goals.Stem Cells.1999;17:191–202.
Morgan RA. Gene therapy for HIV infection.Clin Exp Immunol.1997;107 Suppl 1:41–4.
Cooper D, Penny R, Symonds G, Carr A, Gerlach W, Sun LQ, Ely J. A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins.Hum Gene Ther.1999;10:1401–21.
Johnston JC, Gasmi M, Lim LE, Elder JH, Yee JK, Jolly DJ, Campbell KP, Davidson BL, Sauter SL. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors.J Virol.1999;73:4991–5000.
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.Science.1996;272:263–7.
Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection.Mol Cell Biol.1990;10:4239–42.
Ferry N, Heard JM. Liver-directed gene transfer vectors.Hum Gene Ther.1998;9:1975–81.
Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome.J Virol.1983;45:555–64.
Buller RM, Janik JE, Sebring ED, Rose JA. Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication.J Virol.1981;40:241–7.
Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression.J Virol.1989;63:3822–8.
Chao H, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector.Blood.2000;95:1594–9.
Ponnazhagan S, Weigel KA, Raikwar SP, Mukherjee P, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: erythroid cell-specific delivery and expression of transduced genes.J Virol.1998;72:5224–30.
Minter RM, Rectenwald JE, Fukuzuka K, Tannahill CL, La Face D, Tsai V, Ahmed I, Hutchins E, Moyer R, Copeland EM, 3rd, Moldawer LL. TNF-alpha receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung.J Immunol.2000;164:443–51.
Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration.Hum Gene Ther.1997;8:37–44.
Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy.Hum Gene Ther.1993;4:403–9.
Elkon KB, Liu CC, Gall JG, Trevejo J, Marino MW, Abrahamsen KA, Song X, Zhou JL, Old LJ, Crystal RG, Falck-Pedersen E. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors.Proc Natl Acad Sci USA.1997;94:9814–9.
Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors.J Virol.1993;67:5911–21.
Engelhardt JF, Yang Y, Stratford-Perricaudet LD, Allen ED, Kozarsky K, Perricaudet M, Yankaskas JR, Wilson JM. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with El-deleted adenoviruses.Nat Genet.1993;4:27–34.
Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.Proc Natl Acad Sci USA.1996;93:13565–70.
Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis.Virology.1996;217:11–22.
Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with El and E4 deletions for liver-directed gene therapy.J Virol.1996;70:8934–43.
Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS.Crit Care Med.1996;24:1125–8.
Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction.Crit Care Med.1999;27:1230–51.
Blackwell TS, Blackwell TR, Christman JW. Impaired activation of nuclear factor-kappaB in endotoxin-tolerant rats is associated with down-regulation of chemokine gene expression and inhibition of neutrophilic lung inflammation.J Immunol.1997;158:5934–40.
Doughty LA, Patrene KD, Evans CH, Boggs SS, Robbins PD. Constitutive systemic expression of IL-1Ra or soluble TNF receptor by genetically modified hematopoietic cells suppresses LPS induction of IL-6 and IL-10.Gene Ther.1997;4:252–7.
Kolls J, Peppel K, Silva M, Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer.Proc Natl Acad Sci USA.1994;91:215–9.
Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, Fernandes JC, Martel-Pelletier J. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy.Arthritis Rheum.1997;40:1012–9.
Chernajovsky Y, Adams G, Podhajcer OL, Mueller GM, Robbins PD, Feldmann M. Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor.Gene Ther.1995;2:731–5.
Pruitt JH, Copeland EM, 3rd, Moldawer LL. Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock.Shock.1995;3:235–51.
Ksontini R, MacKay SL, Moldawer LL. Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation.Arch Surg.1998;133:558–67.
Baumhofer JM, Beinhauer BG, Wang JE, Brandmeier H, Geissler K, Losert U, Philip R, Aversa G, Rogy MA. Gene transfer with IL-4 and IL-13 improves survival in lethal endotoxemia in the mouse and ameliorates peritoneal macrophages immune competence.Eur J Immunol.1998;28:610–5.
Yuan Q, Zhao F, Chung SW, Fan P, Sultzer BM, Kan YW, Wong PM. Dominant negative down-regulation of endotoxin-induced tumor necrosis factor alpha production by Lps(d)/Ran.Proc Natl Acad Sci USA.2000;97:2852–7.
Xing Z, Ohkawara Y, Jordana M, Graham FL, Gauldie J. Adenoviral vector-mediated interleukin-10 expression in vivo: intramuscular gene transfer inhibits cytokine responses in endotoxemia.Gene Ther.1997;4:140–9.
Drazan KE, Wu L, Bullington D, Shaked A. Viral IL-10 gene therapy inhibits TNF-alpha and IL-1 beta, not IL-6, in the newborn endotoxemic mouse.J Pediatr Surg.1996;31:411–4.
Giannoukakis N, Rudert WA, Ghivizzani SC, Gambotto A, Ricordi C, Trucco M, Robbins PD. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1 beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro.Diabetes.1999;48:1730–6.
Kang R, Ghivizzani SC, Herndon JH, Robbins PD, Evans CH. Gene therapy for arthritis: principles and clinical practice.Biochem Soc Trans.1997;25:533–7.
Yang GY, Mao Y, Zhou LF, Gong C, Ge HL, Betz AL. Expression of intercellular adhesion molecule 1 (ICAM-1) is reduced in permanent focal cerebral ischemic mouse brain using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist.Brain Res Mol Brain Res.1999;65:143–50.
Taylor BS, Shao L, Gambotto A, Ganster RW, Geller DA. Inhibition of cytokine-induced nitric oxide synthase expression by gene transfer of adenoviral I kappa B alpha.Surgery.1999;126:142–7.
Griesenbach U, Scheid P, Hillery E, de Martin R, Huang L, Geddes DM, Alton EW. Anti-inflammatory gene therapy directed at the airway epithelium.Gene Ther.2000;7:306–13.
Greenberger MJ, Kunkel SL, Strieter RM, Lukacs NW, Bramson J, Gauldie J, Graham FL, Hitt M, Danforth JM, Standiford TJ. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia.J Immunol.1996;157:3006–12.
Abina MA, Tulliez M, Lacout C, Debili N, Villeval JL, Pflumio F, Wendling F, Vainchenker W, Haddada H. Major effects of TPO delivered by a single injection of a recombinant adenovirus on prevention of septicemia and anemia associated with myelosuppression in mice: risk of sustained expression inducing myelofibrosis due to immunosuppression.Gene Ther.1998;5:497–506.
Goebel A, Kavanagh E, Lyons A, Saporoschetz IB, Soberg C, Lederer JA, Mannick JA, Rodrick ML. Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection.Ann Surg.2000;231:253–61.
Conary JT, Parker RE, Christman BW, Faulks RD, King GA, Meyrick BO, Brigham KL. Protection of rabbit lungs from endotoxin injury by in vivo hyperexpression of the prostaglandin G/H synthase gene.J Clin Invest.1994;93:1834–40.
Danel C, Erzurum SC, Prayssac P, Eissa NT, Crystal RG, Herve P, Baudet B, Mazmanian M, Lemarchand P. Gene therapy for oxidant injury-related diseases: adenovirus-mediated transfer of superoxide dismutase and catalase cDNAs protects against hyperoxia but not against ischemia-reperfusion lung injury.Hum Gene Ther.1998;9:1487–96.
Ayala A, Chung C, Xu YX, Evans TA, Redmond KM, Chaudry IH. Increased inducible apoptosis in CD4+ T lymphocytes during polymicrobial sepsis is mediated by Fas ligand and not endotoxin.Immunology.1999;97:45–55.
Hiramatsu M, Hotchkiss RS, Karl IE, Buchman TG. Cecal ligation and puncture (CLP) induces apoptosis in thymus, spleen, lung, and gut by an endotoxin and TNF-independent pathway.Shock.1997;7:247–53.
Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, Korsmeyer SJ, Karl IE. Prevention of lymphocyte cell death in sepsis improves survival in mice.Proc Natl Acad Sci USA.1999;96:14541–6.
Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF, Zollner KM, Buchman TG, Korsmeyer SJ, Karl IE. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis.J Immunol.1999;162:4148–56.
Cohen SB, Crawley JB, Kahan MC, Feldmann M, Foxwell BM. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2.Immunology.1997;92:1–5.
Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, Daugas E, Geuskens M, Kroemer G. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease.J Exp Med.1996;184:1331–41.
Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.Cell.1998;94:481–90.
Matute-Bello G, Liles WC, Radella F, 2nd, Steinberg KP, Ruzinski JT, Jonas M, Chi EY, Hudson LD, Martin TR. Neutrophil apoptosis in the acute respiratory distress syndrome.Am J Respir Crit Care Med.1997;156:1969–77.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Oberholzer, C., Oberholzer, A., Moldawer, L.L. (2001). Gene Therapy Applications for the Treatment of Acute Inflammatory Conditions. In: Factor, P. (eds) Gene Therapy for Acute and Acquired Diseases. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1667-5_13
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1667-5_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5668-4
Online ISBN: 978-1-4615-1667-5
eBook Packages: Springer Book Archive